All reports
Public comment
Prescription Drug Machine-Readable File
Drug pricing policy
Price transparency regulations
Transparency compliance

Turquoise's public comment on CMS-9882-NC

Turquoise's public comment on CMS-9882-NC

Turquoise Health is in full support of the Departments' commitment to broadening price transparency requirements to include prescription drugs. Transparency is ultimately about reducing the financial complexity of healthcare and creating an ecosystem that allows patients to shop for care in advance. Transparent reporting of prescription drug rates is a critical step in building infrastructure that enables patients to receive a comprehensive cost of care before an appointment occurs.

Download PDF

Related resources

Learn, listen, and watch the latest on price transparency.

View all
Turquoise's public comment on CMS 9882-P
Transparency in Coverage (TiC)

Turquoise's public comment on CMS 9882-P

Transparency in Coverage files are on the verge of a much-needed overhaul to become leaner, more organized, and more useful.

Turquoise's public comment on CMS-1834-P
Public comment

Turquoise's public comment on CMS-1834-P

Turquoise Health's public comment on CMS-1834-P supporting comprehensive hospital MRF standards, seeking clarification on new percentile fields, and providing recommendations on EDI 835 ERA transaction data utility. Read our full analysis.

2025 drug reimbursement trends report
Drug pricing data

2025 drug reimbursement trends report

Turquoise Health and ZS's 2025 drug reimbursement trends report analyzes millions of hospital and payer-reported drug rates across 17 products and 4 therapeutic areas revealing how payer-provider dynamics drive reimbursement from 3× to 10× ASP. Explore the data.